Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Sales (2016 - 2025)

Historic Return on Sales for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to 0.78%.

  • Coherus Oncology's Return on Sales fell 53100.0% to 0.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.95%, marking a year-over-year increase of 4000.0%. This contributed to the annual value of 0.11% for FY2024, which is 10300.0% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Return on Sales is 0.78%, which was down 53100.0% from 33.41% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Return on Sales registered a high of 74.05% during Q1 2024, and its lowest value of 2.33% during Q1 2023.
  • In the last 5 years, Coherus Oncology's Return on Sales had a median value of 0.62% in 2021 and averaged 5.49%.
  • As far as peak fluctuations go, Coherus Oncology's Return on Sales soared by 763900bps in 2024, and later tumbled by -752600bps in 2025.
  • Over the past 5 years, Coherus Oncology's Return on Sales (Quarter) stood at 0.62% in 2021, then plummeted by -108bps to 1.3% in 2022, then surged by 33bps to 0.87% in 2023, then surged by 192bps to 0.8% in 2024, then decreased by -3bps to 0.78% in 2025.
  • Its Return on Sales stands at 0.78% for Q3 2025, versus 33.41% for Q2 2025 and 1.21% for Q1 2025.